| Primary |
| Aspergillosis |
23.7% |
| Bronchopulmonary Aspergillosis |
19.4% |
| Fungal Infection |
11.8% |
| Infection |
4.3% |
| Aspergillus Infection |
4.1% |
| Candidiasis |
3.5% |
| Prophylaxis |
3.4% |
| Ill-defined Disorder |
3.2% |
| Pneumonia |
3.0% |
| Pain |
2.9% |
| Pulmonary Mycosis |
2.8% |
| Hypertension |
2.6% |
| Acute Myeloid Leukaemia |
2.5% |
| Drug Use For Unknown Indication |
2.4% |
| Pneumonia Fungal |
2.3% |
| Acute Lymphocytic Leukaemia |
1.8% |
| Antifungal Prophylaxis |
1.7% |
| Lung Transplant |
1.7% |
| Lung Disorder |
1.5% |
| Aspergilloma |
1.4% |
|
| Death |
35.4% |
| Visual Impairment |
4.9% |
| Squamous Cell Carcinoma |
4.4% |
| Vision Blurred |
4.3% |
| Hallucination |
4.2% |
| Pyrexia |
4.1% |
| Disease Progression |
4.0% |
| Respiratory Failure |
3.9% |
| Rhabdomyolysis |
3.9% |
| Pneumonia |
3.6% |
| Drug Ineffective |
3.4% |
| Vomiting |
3.1% |
| Photosensitivity Reaction |
3.0% |
| Renal Failure |
3.0% |
| Visual Disturbance |
3.0% |
| Drug Interaction |
2.7% |
| Interstitial Lung Disease |
2.6% |
| Photophobia |
2.5% |
| No Adverse Event |
2.0% |
| Rash |
2.0% |
|
| Secondary |
| Product Used For Unknown Indication |
15.2% |
| Bronchopulmonary Aspergillosis |
14.8% |
| Aspergillosis |
12.0% |
| Prophylaxis |
8.5% |
| Drug Use For Unknown Indication |
7.6% |
| Infection |
6.2% |
| Fungal Infection |
6.1% |
| Acute Myeloid Leukaemia |
4.5% |
| Pyrexia |
4.0% |
| Systemic Mycosis |
2.8% |
| Sepsis |
2.5% |
| Hiv Infection |
2.1% |
| Pneumonia |
2.0% |
| Hypertension |
1.8% |
| Aspergillus Infection |
1.8% |
| Antifungal Prophylaxis |
1.7% |
| Insomnia |
1.7% |
| Candidiasis |
1.6% |
| Acute Lymphocytic Leukaemia |
1.6% |
| Hodgkin's Disease |
1.6% |
|
| Death |
9.8% |
| Visual Impairment |
8.1% |
| Squamous Cell Carcinoma |
7.2% |
| Rhabdomyolysis |
7.0% |
| Hypoglycaemia |
5.7% |
| Renal Failure |
5.7% |
| Respiratory Failure |
5.4% |
| Vision Blurred |
5.2% |
| Inappropriate Antidiuretic Hormone Secretion |
5.0% |
| Pyrexia |
5.0% |
| Thrombocytopenia |
4.4% |
| Hyponatraemia |
4.1% |
| Interstitial Lung Disease |
3.9% |
| Pancytopenia |
3.9% |
| Renal Impairment |
3.5% |
| Hepatic Function Abnormal |
3.3% |
| Photosensitivity Reaction |
3.3% |
| Septic Shock |
3.3% |
| Visual Disturbance |
3.3% |
| Disease Progression |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.9% |
| Drug Use For Unknown Indication |
15.4% |
| Prophylaxis |
12.5% |
| Acute Myeloid Leukaemia |
6.0% |
| Infection Prophylaxis |
4.1% |
| Acute Lymphocytic Leukaemia |
3.3% |
| Pyrexia |
2.7% |
| Infection |
2.6% |
| Multiple Myeloma |
2.2% |
| Myelodysplastic Syndrome |
2.2% |
| Pneumonia |
1.9% |
| Febrile Neutropenia |
1.9% |
| Prophylaxis Against Graft Versus Host Disease |
1.8% |
| Hypertension |
1.8% |
| Antifungal Prophylaxis |
1.8% |
| Bronchopulmonary Aspergillosis |
1.7% |
| Chronic Lymphocytic Leukaemia |
1.7% |
| Adult T-cell Lymphoma/leukaemia |
1.6% |
| Acute Myeloid Leukaemia Recurrent |
1.5% |
| Pain |
1.5% |
|
| White Blood Cell Count Decreased |
14.0% |
| Sepsis |
13.6% |
| Pneumonia |
10.1% |
| Renal Impairment |
6.1% |
| Pyrexia |
5.9% |
| Respiratory Failure |
5.9% |
| Septic Shock |
5.7% |
| Renal Failure |
4.9% |
| Thrombocytopenia |
4.3% |
| Vomiting |
4.3% |
| Renal Failure Acute |
2.8% |
| Weight Increased |
2.8% |
| Death |
2.6% |
| Febrile Neutropenia |
2.6% |
| Pleural Effusion |
2.6% |
| Stomatitis |
2.6% |
| Toxic Skin Eruption |
2.4% |
| Neutropenia |
2.2% |
| Tachycardia |
2.2% |
| White Blood Cell Count Increased |
2.2% |
|
| Interacting |
| Bronchopulmonary Aspergillosis |
18.4% |
| Fungal Infection |
12.7% |
| Systemic Lupus Erythematosus |
9.2% |
| Cerebral Aspergillosis |
8.9% |
| Product Used For Unknown Indication |
7.0% |
| Aspergillosis |
6.2% |
| Diabetes Mellitus |
5.2% |
| Oral Candidiasis |
5.0% |
| Drug Use For Unknown Indication |
3.6% |
| Prophylaxis |
3.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.0% |
| Hypertension |
2.5% |
| Lung Transplant |
2.5% |
| Pain |
2.2% |
| Tuberculosis |
2.2% |
| Dementia |
1.9% |
| Pyrexia |
1.8% |
| Arthritis |
1.5% |
| Aspergillus Infection |
1.5% |
| Constipation |
1.5% |
|
| Toxicity To Various Agents |
23.5% |
| Drug Interaction |
12.4% |
| Hiccups |
9.8% |
| Liver Disorder |
9.2% |
| Systemic Mycosis |
6.5% |
| Renal Failure Acute |
5.9% |
| Vomiting |
5.2% |
| Sudden Death |
3.9% |
| Immunosuppressant Drug Level Decreased |
2.6% |
| Torsade De Pointes |
2.6% |
| Tremor |
2.6% |
| Drug Level Below Therapeutic |
2.0% |
| Insomnia |
2.0% |
| International Normalised Ratio Increased |
2.0% |
| Thrombosis |
2.0% |
| Toxic Epidermal Necrolysis |
2.0% |
| Wrong Technique In Drug Usage Process |
2.0% |
| Cushing's Syndrome |
1.3% |
| Feeling Abnormal |
1.3% |
| Hypersensitivity |
1.3% |
|
